CoChat

GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease

Open access

Published version of a preprint

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Background: Agonism at the receptor for the glucose-dependent insulinotropic polypeptide (GIPR) is a key component of the novel unimolecular GIPR:GLP-1R co-agonists, which are among the most promising drugs in clinical development for the treatment of obesity and type 2 diabetes. The therapeutic effect of chronic GIPR agonism to treat dyslipidemia and thus to reduce the cardiovascular disease risk independently of body weight loss has not been explored yet. Methods: After 8 weeks on western diet, LDL receptor knockout (LDLR-/-) male mice were treated with daily subcutaneous injections of long-acting acylated GIP analog (acyl-GIP; 10nmol/kg body weight) for 28 days. Body weight, food intake, whole-body composition were monitored throughout the study. Fasting blood glucose and intraperitoneal glucose tolerance test (ipGTT) were determined on day 21 of the study. Circulating lipid levels, lipoprotein profiles and atherosclerotic lesion size was assessed at the end of the study. Acyl-GIP effects on fat depots were determined by histology and transcriptomics. Results: Herein we found that treatment with acyl-GIP reduced dyslipidemia and atherogenesis in male LDLR-/- mice. Acyl-GIP administration resulted in smaller adipocytes within the inguinal fat depot and RNAseq analysis of the latter revealed that acyl-GIP may improve dyslipidemia by directly modulating lipid metabolism in this fat depot. Conclusions: This study identified an unanticipated efficacy of chronic GIPR agonism to improve dyslipidemia and cardiovascular disease independently of body weight loss, indicating that treatment with acyl-GIP may be a novel approach to alleviate cardiometabolic disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-023-01940-2

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Body weight neutral dose of acyl-GIP in LDLR-/- mice. (A) Body weight, (B) change of body composition, (C) cumulative food intake, (D) fasting blood glucose, (E) interperitoneal glucose tolerance and (F) fasting insulin levels of male LDLR-/- mice treated daily with either vehicle or acyl-GIP via subcutaneous injections for 27 days. n = 7. Except for ipGTT (performed at study day 21), plasma parameters were measured from sac blood at study end (day 27). Data represent means ± SEM
Fig. 1 Body weight neutral dose of acyl-GIP in LDLR-/- mice. (A) Body weight, (B) change of body composition, (C) cumulative food intake, (D) fasting blood glucose, (E) interperitoneal glucose tolerance and (F) fasting insulin levels of male LDLR-/- mice treated daily with either vehicle or acyl-GIP via subcutaneous injections for 27 days. n = 7. Except for ipGTT (performed at study day 21), plasma parameters were measured from sac blood at study end (day 27). Data represent means ± SEMCC BY · PubMed Central
Fig. 2 Acyl-GIP ameliorates dyslipidemia and atherosclerotic plaque formation in LDLR-/- male mice. Plasma (A) triglycerides, (B) cholesterol and (C) lipoprotein fractions as well as (D and E) the percentage of plaque area in aortic arches and valves and along the descending aorta of male LDLR-/- mice treated daily with either vehicle or acyl-GIP via subcutaneous injections for 28 days. n = 7. Blood lipids were determined from sac plasma at the end of the study. Data represent means ± SEM. *P < 0.05, **P < 0.01, *** P < 0.001, determined by unpaired two-sided t-test
Fig. 2 Acyl-GIP ameliorates dyslipidemia and atherosclerotic plaque formation in LDLR-/- male mice. Plasma (A) triglycerides, (B) cholesterol and (C) lipoprotein fractions as well as (D and E) the percentage of plaque area in aortic arches and valves and along the descending aorta of male LDLR-/- mice treated daily with either vehicle or acyl-GIP via subcutaneous injections for 28 days. n = 7. Blood lipids were determined from sac plasma at the end of the study. Data represent means ± SEM. *P < 0.05, **P < 0.01, *** P < 0.001, determined by unpaired two-sided t-testCC BY · PubMed Central
Fig. 3 Acyl-GIP regulates adipocyte size and gene expression in subcutaneous fat of LDLR-/- mice. (A) Relative gWAT and iWAT GIPR gene expression of vehicle (gWAT n = 5; iWAT n = 4) and acyl-GIP treated LDLR-/- mice (gWAT n = 5; iWAT n = 4). (B) Volcano plot showing differential expression and its significance (-log10(p-Value), limma-trend) and (C) frequency distribution of adipocyte cell sizes (µm2) of gWAT from acyl-GIP (RNA sequencing n = 5; histology n = 7) versus vehicle (RNA sequencing n = 5; histology n = 6) treated LDLR-/- mice. (D) Volcano plot showing differential expression and its significance (-log10(p-Value), limma-trend) and (E) frequency distribution of adipocyte cell sizes (µm2) of iWAT from acyl-GIP (RNA sequencing n = 5; histology n = 4) versus vehicle treated LDLR-/- mice (RNA sequencing n = 5; histology n = 4). (F) Gene ontologies (p < 0.0001) and KEGG pathways (Pvalue < 0.001) that are down regulated by acyl-GIP in sc fat. Representative terms from Supplementary Table 2 are depicted
Fig. 3 Acyl-GIP regulates adipocyte size and gene expression in subcutaneous fat of LDLR-/- mice. (A) Relative gWAT and iWAT GIPR gene expression of vehicle (gWAT n = 5; iWAT n = 4) and acyl-GIP treated LDLR-/- mice (gWAT n = 5; iWAT n = 4). (B) Volcano plot showing differential expression and its significance (-log10(p-Value), limma-trend) and (C) frequency distribution of adipocyte cell sizes (µm2) of gWAT from acyl-GIP (RNA sequencing n = 5; histology n = 7) versus vehicle (RNA sequencing n = 5; histology n = 6) treated LDLR-/- mice. (D) Volcano plot showing differential expression and its significance (-log10(p-Value), limma-trend) and (E) frequency distribution of adipocyte cell sizes (µm2) of iWAT from acyl-GIP (RNA sequencing n = 5; histology n = 4) versus vehicle treated LDLR-/- mice (RNA sequencing n = 5; histology n = 4). (F) Gene ontologies (p < 0.0001) and KEGG pathways (Pvalue < 0.001) that are down regulated by acyl-GIP in sc fat. Representative terms from Supplementary Table 2 are depictedCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 24

Metadata

Authors
Sachs, S., Götz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M.
Affiliations
  • Helmholtz Munich (DE)
  • Indiana University Bloomington (US)
  • University of Bern (CH)
  • Maastricht University (NL)
Corresponding author
  • Müller, Timo D.
  • Hofmann, Susanna M.
Venue
Cardiovascular Diabetology
Published
2023-08-17
Volume
22
Issue
1
Pages
217-217
ISSN
1475-2840 (ISSN-L)
OpenAlex
W4385913183
Cited by
24
References
30
Citations by year
2026: 10 · 2025: 7 · 2024: 7
FWCI
4.92
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
  • Research Publications (Maastricht University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • mediaTUM (Technical University of Munich) (submittedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
Funders
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
glucose-dependent insulinotropic polypeptide, dyslipidemia, atherosclerosis, LDL receptor knockout mice, cardiovascular disease, cardiometabolic disease, adipocyte lipid metabolism, obesity, type 2 diabetes, weight loss
MeSH terms
Animals, Body Weight, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Male, Receptors, Gastrointestinal Hormone, Weight Loss, Dyslipidemias, Atherosclerosis, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease. https://app.cochat.ai/papers/10.1186/s12933-023-01940-2
The paper
Sachs, S., Götz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2023). GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-023-01940-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.